NCT00858585

Completed

Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients W...

University of Michigan Rogel Cancer Center Source

Compare

Other study identifiers

Sponsor study identifier

UMCC 2008.066

Secondary identifiers

HUM 22831

OTHER · IRBMED

Study Type

observational

Actual enrollment (reported)

149

Locations

1 country

Sites

1

Timeline

Study Start

March 2009

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

May 2011

Actual (reported)

Study Completion

September 2016

Actual (reported)

Brief Summary

This study will examine genes in three different tissues and look for similarities and differences between normal cells and cancer cells. The tissues to be studies come from blood, lymph node and cancer.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 149 participants
Study completion date: September 2016
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
March 2009
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
March 7, 2009
Actual (reported)
First Posted
March 10, 2009
Actual (reported)
Primary Completion
May 2011
Actual (reported)
Study Completion
September 2016
Actual (reported)

Last Updated: October 10, 2019
Status Verified: October 2019
Last Update Submitted: October 8, 2019

Conditions

Breast Cancer

Keywords

Bone metastasis, SNP concordance

Outcome Measures

Primary Outcomes (1)

Single nucleotide polymorphisms
Determine single nucleotide polymorphism concordances between the three DNA specimen sources
time-independent

Eligibility Criteria

Age18 Years+

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

breast cancer patients

You may qualify if:

Age at least 18 years of age

Sponsors & Collaborators

University of Michigan Rogel Cancer Center
Otherlead

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Biospecimen

Retention: SAMPLES WITH DNA

Retained samples will consist of a portion of the specimens collected for this concordance study: peripheral blood leukocytes, lymph nodes, and tumor tissue. All retained samples will be completely de-identified and re-numbered.

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

Catherine Van Poznak, MD
University of Michigan Rogel Cancer Center
PRINCIPAL INVESTIGATOR

Enrollment

149 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: OTHER
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 7, 2009

First Posted

March 10, 2009

Study Start

March 2009

Date type not reported

This date has not been verified as actual or estimated.

NCT00581256

A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer

Phase 1/2Completed

NCT00881361

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Phase 2Completed

NCT02679586

Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy

Early Phase 1Completed

NCT00824733

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2Terminated

NCT00847171

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Phase 2Completed

NCT01477489

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

Phase 1Completed

Able to read and sign the informed consent

Able to provide specimens: one blood draw for white blood cells, provide permission to use tissue already collected.

Contact the study team to confirm eligibility.

Primary Completion

May 2011

Actual (reported)

Study Completion

September 2016

Actual (reported)

Last Updated

October 10, 2019

Record last verified: 2019-10

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00858585
Data provider: ClinicalTrials.gov
Source updated: 2019-10-10
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:19:39 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations